文献速递免疫规划传染病防控与疫情报告

基因型新生儿免疫 priming 增强编码分枝杆菌 Ag85B 的黏膜腺病毒疫苗效果

Gene-based neonatal immune priming potentiates a mucosal adenoviral vaccine encoding mycobacterial Ag85B.
PubMed 文献 · Vaccine · 2016-11-04

结核病仍是全球公共卫生危害,新生儿和婴儿更易感。研究构建表达结核分枝杆菌 Ag85B 的基因疫苗载体,在小鼠出生后早期进行 DNA 疫苗皮内初免,6周龄时经鼻内给予重组腺病毒载体加强。新生儿 DNA 初免后黏膜腺病毒加强可诱导强 Ag85B 特异性 CD4+ 和 CD8+ T 细胞反应,并降低肺部结核攻击后的细菌负荷。

要点

  • 新生儿期 DNA 疫苗皮内初免可诱导针对 Ag85B 的 Th1 型免疫应答,但单独使用不能保护小鼠免受有毒结核分枝杆菌 H37Rv 气溶胶攻击。
  • 6周龄经鼻内给予编码 Ag85B 的重组腺病毒载体,免疫应答中等且保护效果差。
  • 新生儿 DNA 初免后黏膜腺病毒加强可诱导强 Ag85B 特异性 CD4+ 和 CD8+ T 细胞应答,并降低肺部结核攻击后的细菌负荷。

核心结论

  • 新生儿期使用基因疫苗免疫可能创造有利的免疫环境,增强后续编码同一抗原的异源载体疫苗的肺部黏膜加强效果。
  • 生命早期以适当疫苗形式接种分枝杆菌抗原可诱导针对结核分枝杆菌的保护性免疫。

研究设计与样本

  • 研究构建表达结核分枝杆菌 Ag85B 的基因疫苗载体,并在新生小鼠中测试其免疫原性和保护效力。
  • 实验采用异源初免-加强方案,出生后不久给予 DNA 疫苗初免,6周龄时经鼻内给予重组腺病毒载体加强。

主要发现

  • 新生儿小鼠皮内接种 DNA 疫苗可诱导针对 Ag85B 的 Th1 型免疫应答,但未能保护小鼠免受后续有毒结核分枝杆菌 H37Rv 气溶胶攻击。
  • 6周龄经鼻内给予编码 Ag85B 的重组腺病毒载体产生中等免疫应答,保护效果差。
  • 新生儿 DNA 初免后黏膜腺病毒加强产生强 Ag85B 特异性 CD4+ 和 CD8+ T 细胞应答,在肺相关淋巴结和脾脏中均可见, responding 细胞具有分泌多种抗菌因子的能力。
  • 该初免-加强方案改善保护效果,表现为肺部结核攻击后细菌负荷降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tuberculosis remains a major public health hazard worldwide, with neonates and young infants potentially more susceptible to infection than adults. BCG, the only vaccine currently available, provides some protection against tuberculous meningitis in children but variable efficacy in adults, and is not safe to use in immune compromised individuals. A safe and effective vaccine that could be given early in life, and that could also potentiate subsequent booster immunization, would represent a significant advance. To test this proposition, we have generated gene-based vaccine vectors expressing Ag85B from Mycobacterium tuberculosis (Mtb) and designed experiments to test their immunogenicity and protective efficacy particularly when given in heterologous prime-boost combination, with the initial DNA vaccine component given soon after birth. Intradermal delivery of DNA vaccines elicited Th1-based immune responses against Ag85B in neonatal mice but did not protect them from subsequent aerosol challenge with virulent Mtb H37Rv. Recombinant adenovirus vectors encoding Ag85B, given via the intranasal route at six weeks of age, generated moderate immune responses and were poorly protective. However, neonatal DNA priming following by mucosal boosting with recombinant adenovirus generated strong immune responses, as evidenced by strong Ag85B-specific CD4+ and CD8+ T cell responses, both in the lung-associated lymph nodes and the spleen, by the quality of these responding cells (assessed by their capacity to secrete multiple antimicrobial factors), and by improved protection, as indicated by reduced bacterial burden in the lungs following pulmonary TB challenge. These results suggest that neonatal immunization with gene-based vaccines may create a favorable immunological environment that potentiates the pulmonary mucosal boosting effects of a subsequent heterologous vector vaccine encoding the same antigen. Our data indicate that immunization early in life with mycobacterial antigens in an appropriate vaccine setting can prime for protective immunity against Mtb.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Dai G, Rady HF, Huang W, et al. Gene-based neonatal immune priming potentiates a mucosal adenoviral vaccine encoding mycobacterial Ag85B. Vaccine. 2016. PMID: 27823900. doi:10.1016/j.vaccine.2016.10.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。